JPH0656659A - Pharmaceutical composition which can be directly made into tablet and preparation of said tablet - Google Patents

Pharmaceutical composition which can be directly made into tablet and preparation of said tablet

Info

Publication number
JPH0656659A
JPH0656659A JP19261592A JP19261592A JPH0656659A JP H0656659 A JPH0656659 A JP H0656659A JP 19261592 A JP19261592 A JP 19261592A JP 19261592 A JP19261592 A JP 19261592A JP H0656659 A JPH0656659 A JP H0656659A
Authority
JP
Japan
Prior art keywords
tablet
acetaminophen
fluidized bed
polyvinylpyrrolidone
pvp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP19261592A
Other languages
Japanese (ja)
Inventor
Min Tsua Shii
ミン ツァ シィ
So Chun Chen
ソ チュン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATL SCI KAUNSHIRU
National Science Council
Original Assignee
NATL SCI KAUNSHIRU
National Science Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATL SCI KAUNSHIRU, National Science Council filed Critical NATL SCI KAUNSHIRU
Priority to JP19261592A priority Critical patent/JPH0656659A/en
Publication of JPH0656659A publication Critical patent/JPH0656659A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE: To provide an acetoaminophene tablet having characteristic including particularly high hardness and short elution time. CONSTITUTION: This table is produced from (a) acetoaminophene of 85 to 95% w/w of the dry weight of the entire compsn., (b) polyvinyl pyrrolidone(PVD) of 4 to 5% w/w of the dry weight of the entire compsn., (c) a disintegrator of 1 to 10% w/w of the dry weight of the entire compsn. and (d) a suitable amt. of a preferable lubricant. The acetoaminophene is put into a fluidized bend granule producing device and a soln. of 5 to 10% polyvinyl pyrrolidone(PVD) is sprayed to the fluidized bed. The fluidized bed is dried to its humidity of 0.5 to 2% w/w and finally, the disintegrator is added and the mixture is directly tableted.

Description

【発明の詳細な説明】 【0001】 【産業上の利用分野】本発明は錠剤の製造法,特に高い
硬度,短い溶離時間な特徴を持つアセトアミノフェン
(Acetaminophen)原名はジアセチル−P
−アミノフェノール(acetyl−P−aminop
henol)粉状の賦形剤,結合剤,または崩壊剤など
を加えて均質にし、錠剤器で圧縮して円盤状に固めたも
のである、錠剤の製造法の改良に関する。 【0002】 【従来の技術】一般に錠剤の製剤関係の基本的欠点は顆
粒の流動性が良くない,溶解速度が遅い,錠剤がキヤッ
ピング(capping)する崩壊性をわるくしなどが
あり,それに対して解決する方法は結合剤、崩壊剤及び
滑沢剤など適当な物質を選ぶ、または製造法の改良しか
できません。錠剤,主としては圧縮錠剤のみであり,錠
剤の製造工程は乾式法,または乾式顆粒圧縮法,湿式
法,湿式顆粒圧縮法の4種類がある。乾式法は薬品を賦
形剤また崩壊剤などを加えて均等に混合する。低速度の
圧縮機で強圧成形し、薄い、大きな平たい圧製錠剤を製
造し、それを砕いて、ふるい一定の大きさ顆粒を得る方
法。乾式顆粒圧縮法というのは乾式法で得られた顆粒が
直接圧縮機により強圧して製錠方法。この二種類の方法
は水分の混合により変化やすい薬品,または加熱乾燥の
できない薬品を用いられません。すなわち薬品は吸湿力
があつて、流動性が低く。または粉末のかさが高すぎで
直接圧縮に強圧できないことがありまして,湿式法や湿
式顆粒圧縮法の錠剤製造工程を行なわれませんです。そ
の時,一般的に湿式法や湿式顆粒法を用いられ、湿式顆
粒圧縮法は賦形剤,崩壊剤を水で混合し、または液態の
結合剤を薬品に添加して、適当な大きさの軟塊をつく
り、顆粒機やふるいを押通して顆粒を製造して乾燥す
る,乾燥後大きな顆粒は砕いて,一定の大きさのみを集
め滑沢剤を加えて打錠機で製錠する。 【0003】湿式法は薬品の顆粒の大小を大きくなる,
静電引力を削減なる,または薬品の流動性を良くなるな
ど優点がある。すなわち高含量の結合剤を添加して,錠
剤の硬度また適量の崩壊剤から溶解速率を増加する。し
かし湿式法の製剤工程は時間かかりし、その過程にコン
トロールが易くない欠点もある。湿式法の欠点を改善し
ようなことは処方に改良しかできない。乾式法は湿式法
により製剤工程の過程に水分を使用しない,熱つを加え
れないことがあり。その為に製剤の時間が短くなる,エ
ネルギーも節約でき,しかし乾式法で一定の大きさ顆粒
を得る為に,圧製錠粉砕によって細い粉末があつて産率
が低く,または細い粉末が回収しなければなりませんこ
ともある。 【0004】 【本発明が解決しようとする課題】上記乾式法,乾式顆
粒圧縮法の製剤工程で圧縮製錠に粉砕すると細い粉末が
生じ,や産率が低く,または成形困難な薬品に対して錠
剤の硬度が不足な問題が存在すること,それを解決する
に一般は製剤工程の装置を改良しよう方法で,しかし効
果が得られなかった。例えば常用なサクチル酸のような
解熱鎮痛薬アセトアミノフェン(Acetaminop
hen),すなわちジアセチル−P−アミノフェノール
(N−acetyl−P−aminophenol),
その薬品の物理性質は白色結晶または結晶性粉末で粉末
の流動性が不良,顆粒ならない,または製剤工程にキヤ
ツピング(capping)ことなどの多く欠点があ
り,その欠点を改善する為にアセトアミノフェンの処方
に改良して、錠剤の硬さを硬くしたり,溶離時間を短縮
たりのような解決方法は望まれている。アセトアミノフ
ェンとカルボキシメチルセルロース(carbboxy
methyl cellulose,CNC)混合し
てからもプレゲラチン化デンプン(pregelati
nized starch)溶液を加える。90%アセ
トアミノフェン製品ができ,米国特許第4439453
号明細書に記載されており,また賦形剤としてスチアリ
ソ酸(stearic acid)が用いられる,特別
な噴霧乾燥法で90%アセトアミノフェン製品が米国特
許第4600579号に記載されており,または流動床
方法で粘合剤としてプレゲラチン化デンプン(preg
eltinized starch)を用いられ,90
%アセトアミノフェンを含有した直接打錠できる薬学組
成は米国特許第4757,090に記載されて,粘合剤
としてポリビニルピロリドン(PVP)をイソプロピル
アルコール(isopropyrol alcoho
l)に溶けて作,た溶液を用いられ,含有アセトアミノ
フェン塊状打錠できる薬学組成物もあり:(DrugD
evelp & Ind.pharm.15(8)PP
1751:参照),しかしその方法はポリビニルピロ
リドン(PVP)水溶液でアセトアミノフェン粉末の性
質を完全に改善することができません。 【0005】 【課題を解決するための手段】本発明者らはポリビニル
ピロリドン(PVP)水溶液は粘合剤としでアセトアミ
ノフェン粉末に添加して直接打錠できる薬学組成物を得
られた特に滑沢剤を含むかとうが本発明の薬学組成物に
及ばない。その具体例としては流動床顆粒乾燥器に置い
たアセトアミノフェンの上にポリビニルピロリドン(P
VP)5〜10w/v%を噴霧して湿度0.5〜2%w
/wまでに乾燥して,崩壊剤や滑沢剤を加え均一に練合
した後,直接打錠により製剤できる,その錠剤の硬さが
高くて溶離時間が短くとした。従来アセトアミノフェン
を含有して直接打錠で製作した錠剤組成物は大きい結晶
アセトアミノフェンを直接打錠の賦形剤に混合した薬学
組成物を使用したり,または高いアセトアミノフェン含
有量の直接打錠薬学組成物を製備たり,二種類がある。
前記の大きい結晶を直接打錠の賦形剤を混合する場合に
は,アセトアミノフェンの溶離時間が掛る欠点がある。
もしく小い結晶アセトアミノフェンを用いられるとして
は,その後かなり大量な直接打錠賦形剤を混合しなけれ
ばならない,また製造工程に面倒たり,経済にコストを
増加たりなどの欠点がある。その結果が先行技術に述べ
たVogelにより(carb boxy methy
l cellulose,CMC)とアセトアミノフェ
ンを混合後,デンプン溶液をアセトアミノフェンに噴霧
の製造法,あるいはステアリ酸を賦形剤として90%ア
セトアミノフェンの直接打錠薬学組成物の製造法,或は
Patelにより粘合剤としてポリビニルピロリドン
(PVP)をイソプロピル(isopropyrol)
に溶けてアセトアミノフェン薬学組成物の製造法などが
色色あつても,高い硬度,短い溶離時間のできるアセト
アミノフェン薬学組成物を製造することが難しいであ
る。 【0006】本発明者らは前記のアセトアミノフェン薬
学組成物の欠点を解すべく鋭意研究の結果,流動床顆粒
製造法により粘合剤としてポリビニルピロリドン(PV
P)水溶液を用いられ,適当な崩壊剤を加え,アセトア
ミノフェンの直接打錠薬学組成物を発明した。本発明に
ポリビニルピロリドン(PVP)を粘合剤として使用し
たことは先行技術に用いられたデンプン(carb b
oxy−methyl cellulose,CM
C),ポリビニルピロリドン(PVP)のイソプロピル
(isopropyrol)溶液とも違い。本発明の製
造工程にある顆粒の製造法は前述技術の噴霧乾燥法が違
いし本発明アセトアミノフェン,ポリビニルピロリドン
(PVP)を含む組成物は一種崩壊剤だけを加え,先行
技術はアセトアミノフェン賦形剤、粘合剤、崩壊剤、潤
湿剤、滑沢剤などを含むことも違い。本発明の顆粒製造
法薬学組成物の原料は先行技術と異なりことが明られで
その特徴は硬度を向上させて溶離時間を短縮させること
である。 【0007】以下に本発明の特徴について具体的に説明
する,その先に粉末と錠剤の物理恒数の測定法を説明す
る。「直接打錠」とは薬物組成物が賦形剤を加えられ,
従来の製造工程の方法,装置を用いて直接打錠できるこ
と,その錠剤の硬さや硬度計の測量値を示すときに用い
る単位でKgを用いる。 「顆粒安息角(゜)」:同し粒度の顆粒が漏斗から流れ
た,その容器底面の面積,高度を精密に量る,正接値を
計算して,顆粒の安息角を求める,同様の方法で3回繰
り返し測定し,平均安息角を算出する。「顆粒粒度分布
%」本組成物約50gを精密に量り,3分間20〜10
0mesh(tyler)ふるいを通過した,Erwe
kaのRotap振盪機に入れ,粒度分布を求める。 【錠剤硬度(Kg)】Erweka硬度計を用いて;バ
ネガ圧縮されるとその力が錠剤の直径方向にかかり錠剤
が破壊されたときの圧力を読み取る,10回繰り返し測
定して,平均硬度を算出する。 【錠剤摩損度(%)】Roche錠剤摩損度測定器に1
0個錠剤を入れる,4分間に回転させた後,その錠剤を
取り出して破損分離した粉末,および小粒子を篩別除去
して,重量を測定し,重量減をもとの重量に対する百分
率で表示する,3回繰り返し測定し平均摩損度を算出す
る。 【錠剤溶離時間(分)】日本分光会社DT−610の溶
離度測定器を用い,米国薬局方(USP)第XXI版の
試験方法で錠剤溶離時間を測定する,6回繰り返し測定
し平均値を算出する。 【錠剤の重量偏差(%)】Mettler AE240
精密電子分析はかりを用い,米国薬局方(USP)第X
XI版の試験方法で重量を測定し平均重量を算出して,
その重量偏差率を求める。 【0008】アセトアミノフェン組成物の成分について
説明する。アセトアミノフェンは無色,顆粒密度か低く
い結晶,顆粒凝集粉が無視できる状態となり,圧縮しに
くい性質があるので,本発明はポリビニルピロリドン
(PVP)溶液を用いられる,そのPVP溶液たげ滑沢
剤が無添加にもアセトアミノフェンは流動乾燥方式で
0.5〜2%水分が保存でき,このアセトアミノフェン
組成物は直接打錠すると硬度が高く溶離時間が短くな錠
剤が製造できる。ポリビニルピロリドン(PVP)は無
色ないし黄色,薄色の粉末,その分子量は触媒量,反応
温度,反応時間などの条件を調節上によって10,00
0ないし1,200,000がある,ポリビニルピロリ
ドン(PVP)は水に溶かしでわずかに酸性溶液になり
非イオン性,かなり性質の安定な樹脂である。その溶液
はセルロース誘導体を混合する場合にはアセトアミノフ
ェン顆粒の分散安定性が増加することが注目すべきであ
る。本発明はポリビニルピロリドン(PVP)溶液を用
いられ,流動床造粒法で製造したアセトアミノフェン,
周知技術の結晶セルロースを利用することに比較する
と,本発明は乾式顆粒製造方法を用られる場合,湿式法
で顆粒を砕き細い粉末が出すことが抑制できる,また産
量も増加できる,錠剤型の硬度も増加できるなどの優点
がある。 【0009】本発明は一種高い硬度,短い溶離時間,直
接打錠でき,流動性よいなど特徴を持つアセトアミノフ
ェン薬学組成物に関する。この組成物は(a)N−ジア
セチル−P−アミノフェノール(b)ポリビニルピロリ
ドン(PVP)を含む。本発明は直接打錠できる為に全
体組成物の乾燥重量に対してアセトアミノフェンは85
〜90%w/w,ポリビニルピロリドン(PVP)は4
〜5%,崩壊剤は1〜10%w/w,更に滑沢剤を添加
してもよい。本薬学組成物各々成分は具体的に説明す
る。アセトアミノフェンはaerosil▲R▼200
0(Degussa会社の二酸化珪素,Silicon
edioxide)と混合して,80meshぶるいお
よび100meshぶるいを通過するものである。ポリ
ビニルピロリドン(PVP)はドイツのBASF会社製
品,crospovidone▲R▼,または米国のG
AF会社の製品で,その中には米国薬局方第XXI版で
規定しているものを好ましい。本発明薬学組成物は(P
VP)を含んで組成物の流動性と結合性を調整する,そ
の添加量によって5Kg以上硬度,1%以下キヤツピン
グ率を得られる。全体組成物の重量に対して一般的には
2%なしい10%のポリビニルピロリドン(PVP)を
添加してよい,本発明には3%なしい6%の添加量が好
ましい。水中または胃液中でアセトアミノフェン組成物
に短い溶離時間をあたえる為にでんぷん,ポリビニルピ
ロリドン(PVP),デンプン水酸基エチルナトリウ
ム,ゲラチン化デンプンは崩壊剤として用いられる。全
体組成物の重量に対して一般にはcrospovido
ne,デンプンエチレンオキシドナトリウム1〜3%を
添加しプレゲラチン化デンブンには3〜10%を添加し
てよい。滑沢剤の添加については打錠の際,薬品がきね
ヤラすとに付着しないようにし,また圧縮中の圧力伝達
性を高める働きをする。適量の滑沢剤の添加により打錠
は非常に容易となり,また表面の美しい錠剤ができる,
しかしその添加量が多すぎると硬度が低下する,本発明
に応じて添加する滑沢剤がステアリン酸,またはステア
リン酸マグネシウム,精製タルクステアリン酸などの金
属塩,例え,ナトリウム,カルシウム,亜鉛。全体組成
物の重量に対して一般的には0.10%ないし1.0%
の量を添加しよう,本発明には0.5%ないし1.0%
の添加量が望ましい。前記組成物を直接打錠してできた
錠剤は5Kgの硬度,または20分間に80%アセトア
ミノフェンが溶離できすることを特徴とする。 【表1】 【表2】本発明は流動床顆粒製造法によってアセトアミノフェン
組成物を製造する。先に適当な流動床を選ぶ,予めて珪
酸塩を混合したアセトアミノフェン粉末を流動床の上に
置き,その完全温度が上昇まで流動化し,その先にポリ
ビニルピロリドン(PVP)はふに溶かした5w/w%
溶液を製備し,流動床上のアセトアミノフェン粉末に噴
霧し,crospovidone,ないし崩壊剤,また
はマグネシウムステアリン酸ないし滑沢剤を加えて,湿
度は0.5〜2重量百分率まで流動化して,Glatt
Quickふるいなどを用いられ,期望な粒径分布を
製作し,前述の過程に述べた崩壊剤,滑沢剤PVPが錐
筒混合器に入れ充分混合する。本発明直接打錠できるア
セトアミノフェン薬学組成物の製備方法は下記の過程を
含み。 (A)ジアセチル−P−アミノフェノールを流動床顆粒
乾燥器の中に入れて (B)polyvinylpyrrolidoneを水
で溶け,5〜10w/v%溶液にして,この溶液は20
〜35%流動床にしてありジアセチル−P−アミノフェ
ノール粉末に噴霧して (C)噴霧させたジアセチル−P−アミノフェノール粉
末は湿度0.5〜2重量百分率まで乾燥する (D)1〜5%崩壊剤を加えて (E)湿度は0.5〜2重量百分率まで以上の各成分は
充分に混合させる。 (F)直接打錠する。 本発明に流動床で顆粒製備まる操作条件は,25ないし
45℃まで加熱した空気が流動床の下から上がり,その
襟弁の開け閉め,温度の調整またポリビニルピロリドン
(PVP)溶液のスプレイ速率などが適当に調整する。
製作したアセトアミノフェン顆粒の粒径は。ポリビニル
ピロリドン(PVP)溶液のスプレイ圧力や流動床の含
水量により変化し,その調整参数は粒径を影響するもし
Glatt Quickふるいなどを用いられ,固定粒
径になる。本発明の目的,特徴および利点は例として示
す,いくつかの実施例があつても,それ故に本発明を何
ら制限するものではない。錠剤硬度は10個錠剤硬度の
平均値で,錠剤重量は20個錠剤重量の平均値である。 実例1〜3 アセトアミノフェン組成物顆粒流動床造粒乾燥機(Gl
att Air Techniques,Inc.GP
CG−1)。機械参数と処方参数は第3表に示すよう,
粒径分布(particle size)と累積比(c
umulative percent retaine
d)は第4表に示すような条件で試験した。その結果は
ポリビニルピロリドン(PVP)水溶液の濃度は5%と
7.5%w/vの流動性が直接打錠できる。 【表3】【表4】 実例4〜6 次の第5表に示す試料を用いて直接打錠薬物組成物を製
造し,その性質は第6表に示すよう: 【表5】 【表6】
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing tablets, particularly acetaminophen, which is characterized by high hardness and short elution time, and is originally named diacetyl-P.
-Aminophenol (acetyl-P-aminop
and a powdery excipient, a binder, a disintegrating agent or the like to make the mixture homogeneous, and the mixture is compressed with a tablet machine to be solidified into a disk shape. [0002] In general, the basic drawbacks associated with the formulation of tablets include poor flowability of granules, slow dissolution rate, and disintegration of tablets by capping. The only way to solve it is to select appropriate substances such as binders, disintegrants and lubricants, or improve the manufacturing method. Only tablets, mainly compressed tablets, and there are four types of tablet manufacturing processes: a dry method, a dry granule compression method, a wet method, and a wet granule compression method. In the dry method, the drug is mixed with an excipient or a disintegrant and mixed evenly. A method of forming a thin, large flat tablet by high-pressure molding with a low-speed compressor and crushing it to obtain granules having a sieve of a constant size. The dry granule compression method is a tableting method in which the granules obtained by the dry method are directly compressed with a compressor. These two methods do not use chemicals that change easily by mixing water or chemicals that cannot be heated and dried. That is, the chemicals have hygroscopicity and low fluidity. Or the powder is too bulky to press directly for compression, and the tablet manufacturing process of wet method or wet granule compression method is not performed. At that time, generally, a wet method or a wet granule method is used. In the wet granule compression method, an excipient and a disintegrant are mixed with water, or a liquid binder is added to a chemical to soften an appropriate size. A lump is made, and the granules are passed through a granulator or a sieve to produce granules and dried. After drying, the large granules are crushed, only a certain size is collected, a lubricant is added, and the mixture is tableted with a tableting machine. The wet method increases the size of drug granules,
There are advantages such as reducing electrostatic attraction or improving the fluidity of chemicals. That is, a high content of binder is added to increase the tablet hardness or the dissolution rate from an appropriate amount of disintegrant. However, there is a drawback in that the wet process formulation process takes time and the process is not easy to control. Remedies for the wet process can only improve the formulation. The dry method does not use water in the process of formulation process due to the wet method and may not be able to add heat. As a result, formulation time is shortened and energy can be saved. However, in order to obtain granules of a certain size by the dry method, fine powder is produced by crushing tablet presses, resulting in a low production rate or recovery of fine powder. There are some things that must be done. [0004] In the formulation process of the above dry method and dry granule compression method, when crushed into a compressed tablet, a fine powder is produced, and the chemical yield is low or difficult to mold. The problem of insufficient tablet hardness exists, and in order to solve the problem, it was generally a method of improving the equipment of the formulation process, but the effect was not obtained. Antipyretic analgesics acetaminophen (acetaminop), such as the conventional succinic acid
hen), that is, diacetyl-P-aminophenol (N-acetyl-P-aminophenol),
The physical properties of the drug are white crystals or crystalline powder, which has many drawbacks such as poor fluidity of powder, non-granulation, or capping in the formulation process. Solutions such as improved formulation to increase tablet hardness and shorten elution time are desired. Acetaminophen and carboxymethyl cellulose (carbboxy
pregerlatinized starch (pregelati) after mixing with methyl cellulose (CNC)
The sized solution) is added. 90% acetaminophen product is produced, US Pat. No. 4,439,453
90% acetaminophen product is described in US Pat. No. 4,600,579 by a special spray drying method described in US Pat. Pregelatinized starch as a binder by the floor method (preg
Electrified Starch), 90
A directly tabletable pharmaceutical composition containing% acetaminophen is described in US Pat. No. 4,757,090, wherein polyvinylpyrrolidone (PVP) is used as a binder and isoprolol alcohol.
There is also a pharmaceutical composition which can be made into a bulk tablet containing acetaminophen by using a solution prepared by dissolving it in (l): (DrugD
evelp & Ind. pharm. 15 (8) PP
1751 :), but that method cannot completely improve the properties of acetaminophen powder with an aqueous polyvinylpyrrolidone (PVP) solution. The inventors of the present invention obtained a pharmaceutical composition which can be directly tableted by adding an aqueous polyvinylpyrrolidone (PVP) solution as a binder to acetaminophen powder to obtain a pharmaceutical composition. It does not extend to the pharmaceutical composition of the present invention even if it contains a lubricant. A specific example is polyvinylpyrrolidone (P) on acetaminophen placed in a fluid bed granulator dryer.
VP) 5-10 w / v% is sprayed and the humidity is 0.5-2% w
/ W, and a disintegrating agent and a lubricant were added and uniformly kneaded, and then directly tableted. The tablets were high in hardness and short in elution time. Conventional tablet compositions prepared by direct compression containing acetaminophen may use a pharmaceutical composition in which large crystalline acetaminophen is directly mixed with a tableting excipient, or may have a high acetaminophen content. There are two types of direct compression pharmaceutical compositions.
When the above-mentioned large crystals are directly mixed with a tableting excipient, there is a drawback that the elution time of acetaminophen is long.
If small crystalline acetaminophen is used, there are drawbacks such that a considerably large amount of direct compression excipient must be mixed thereafter, the manufacturing process is troublesome, and the cost is increased economically. As a result, according to Vogel described in the prior art (carb boxy methy
Cellulose (CMC) and acetaminophen and then a starch solution is sprayed onto acetaminophen, or a direct compression pharmaceutical composition of 90% acetaminophen with steariic acid as an excipient, or Is polyvinylpyrrolidone (PVP) isopropyl as a binder by Patel.
It is difficult to manufacture an acetaminophen pharmaceutical composition which has high hardness and a short elution time even if the method for producing an acetaminophen pharmaceutical composition is dissolved in water. The inventors of the present invention have conducted intensive studies to solve the above-mentioned drawbacks of the pharmaceutical composition of acetaminophen. As a result, polyvinylpyrrolidone (PV
P) An aqueous solution was used and an appropriate disintegrant was added, and a pharmaceutical composition for direct compression of acetaminophen was invented. The use of polyvinylpyrrolidone (PVP) as a binder in the present invention means that the starch used in the prior art (carb b
oxy-methyl cellulose, CM
C), different from the isopropyl solution of polyvinylpyrrolidone (PVP). The manufacturing method of the granules in the manufacturing process of the present invention is different from the spray drying method of the above-mentioned technique, and the composition containing acetaminophen and polyvinylpyrrolidone (PVP) of the present invention includes only one disintegrant, and the prior art is acetaminophen. It is also different in that it contains excipients, binders, disintegrants, moisturizers, lubricants, etc. It has been revealed that the raw material of the pharmaceutical composition of the present invention for producing granules is different from the prior art, and its characteristic is to improve hardness and shorten elution time. The features of the present invention will be specifically described below, and the method for measuring the physical constants of the powder and tablet will be described first. "Direct compression" means that the drug composition is added with excipients,
Kg is used as a unit used when tableting can be directly performed using a conventional manufacturing method and apparatus, and hardness of the tablet and a measured value of a hardness meter are used. "Granule repose angle (°)": Granules of the same particle size flowed from the funnel, the surface area and height of the container were precisely measured, and the tangent value was calculated to obtain the repose angle of the granule. Repeat the measurement three times with to calculate the average angle of repose. "Granule particle size distribution%" About 50 g of this composition is precisely weighed, and it is 20 to 10 for 3 minutes.
Erwe passed through 0 mesh (tyler) sieve
Put it in a Ka Rotap shaker and determine the particle size distribution. [Tablet hardness (Kg)] Using an Erweka hardness meter; when the spring compression is applied, the force is applied in the diametrical direction of the tablet, and the pressure when the tablet is broken is read. Repeated measurement is repeated 10 times to calculate the average hardness. To do. [Tablet friability (%)] 1 for the Roche tablet friability meter
Insert 0 tablets, rotate for 4 minutes, take out the tablets, remove the powder and small particles that have been broken and separated by sieving, measure the weight, and display the weight loss as a percentage of the original weight. Yes, repeat the measurement three times to calculate the average friability. [Tablet elution time (minutes)] The tablet elution time is measured by the test method of the United States Pharmacopeia (USP) Version XXI using the elution meter of JASCO Corporation DT-610. The average value is obtained by repeating the measurement six times. calculate. [Table Tablet weight deviation (%)] Mettler AE240
Using a precision electronic analysis scale, USP (USP) X
Measure the weight with the test method of XI version, calculate the average weight,
The weight deviation rate is calculated. The components of the acetaminophen composition will be described. Since acetaminophen is colorless, has a low granular density, has a crystal that can be neglected, and has a property of being difficult to compress, a polyvinylpyrrolidone (PVP) solution is used in the present invention. However, 0.5 to 2% water content of acetaminophen can be stored by a fluidized drying method without addition, and when this acetaminophen composition is directly tableted, a tablet having high hardness and short elution time can be produced. Polyvinylpyrrolidone (PVP) is a colorless to yellow, light-colored powder, the molecular weight of which is controlled by adjusting the amount of catalyst, reaction temperature, reaction time, etc.
Polyvinylpyrrolidone (PVP), which has 0 to 1,200,000, is a nonionic, fairly stable resin that dissolves in water to form a slightly acidic solution. It should be noted that the solution increases the dispersion stability of acetaminophen granules when mixed with the cellulose derivative. The present invention uses a polyvinylpyrrolidone (PVP) solution and uses acetaminophen produced by a fluidized bed granulation method.
Compared with the use of well-known crystalline cellulose, the present invention, when using the dry granule manufacturing method, can suppress the granulation of the granules by the wet method to produce a fine powder, and increase the production amount. There is an advantage that you can increase. The present invention relates to an acetaminophen pharmaceutical composition having a high hardness, a short elution time, direct tableting and good fluidity. The composition comprises (a) N-diacetyl-P-aminophenol (b) polyvinylpyrrolidone (PVP). Since the present invention can be directly tableted, acetaminophen is 85% by dry weight of the entire composition.
~ 90% w / w, polyvinylpyrrolidone (PVP) is 4
.About.5%, disintegrant 1 to 10% w / w, and a lubricant may be added. Each component of the pharmaceutical composition will be specifically described. Acetaminophen is aerosil ® 200
0 (Degussa company's silicon dioxide, Silicon
It is mixed with edioxide) and passed through 80 mesh sieve and 100 mesh sieve. Polyvinylpyrrolidone (PVP) is a German BASF company product, crospovidone®, or US G
AF company products, of which those prescribed in US Pharmacopeia XXI version are preferred. The pharmaceutical composition of the present invention is (P
VP) is included to adjust the fluidity and bondability of the composition. Depending on the amount added, a hardness of 5 kg or more and a capping rate of 1% or less can be obtained. Generally 2% to 10% polyvinylpyrrolidone (PVP) may be added, based on the weight of the total composition, an addition amount of 3% to 6% being preferred for the present invention. Starch, polyvinylpyrrolidone (PVP), starch hydroxyethyl sodium, and gelatinized starch are used as disintegrants in order to give a short elution time to the acetaminophen composition in water or gastric juice. Generally crospovido based on weight of total composition
ne, 1 to 3% of sodium starch ethylene oxide may be added, and 3 to 10% may be added to the pregelatinized denbun. Regarding the addition of a lubricant, it prevents the chemicals from adhering to the shavings during tableting, and also enhances the pressure transmission during compression. Tableting becomes very easy by adding an appropriate amount of lubricant, and tablets with a beautiful surface can be produced.
However, if the added amount is too large, the hardness decreases. The lubricant added according to the present invention is stearic acid or a metal salt such as magnesium stearate or purified talc stearic acid, for example, sodium, calcium or zinc. Generally 0.10% to 1.0% by weight of the total composition
Amount of 0.5% to 1.0% for the present invention
Is desirable. A tablet obtained by directly compressing the composition is characterized by having a hardness of 5 Kg or being capable of eluting 80% acetaminophen in 20 minutes. [Table 1] [Table 2] The present invention produces an acetaminophen composition by a fluid bed granule manufacturing method. First, choose an appropriate fluidized bed. Place acetaminophen powder mixed with silicate in advance on the fluidized bed, fluidize it until its complete temperature rises, and then dissolve polyvinylpyrrolidone (PVP) in the oven. 5w / w%
Prepare the solution, spray on acetaminophen powder on the fluidized bed, add crospovidone, or disintegrant, or magnesium stearic acid or lubricant, fluidize the humidity to 0.5 to 2 weight percent, and add Glatt.
A Quick sieve or the like is used to produce a desired particle size distribution, and the disintegrant and lubricant PVP described in the above process are put into a conical cylinder mixer and mixed sufficiently. The method for preparing the acetaminophen pharmaceutical composition which can be directly tabletted according to the present invention includes the following steps. (A) Diacetyl-P-aminophenol was placed in a fluid bed granulator dryer, and (B) polyvinylpyrrolidone was dissolved in water to make a 5-10 w / v% solution, and this solution was 20
~ 35% fluidized bed sprayed onto diacetyl-P-aminophenol powder (C) Sprayed diacetyl-P-aminophenol powder is dried to a humidity of 0.5 to 2 weight percent (D) 1 to 5 % Disintegrant is added and (E) the humidity is 0.5 to 2% by weight. The above components are sufficiently mixed. (F) Tablet directly. In the present invention, the operating conditions for preparing granules in a fluidized bed are as follows: air heated to 25 to 45 ° C. rises from under the fluidized bed, the collar valve is opened and closed, the temperature is adjusted, and the spray rate of polyvinylpyrrolidone (PVP) solution is set. Adjust appropriately.
What is the particle size of the produced acetaminophen granules? It changes depending on the spray pressure of the polyvinylpyrrolidone (PVP) solution and the water content of the fluidized bed, and the adjusted parameter influences the particle size. If a Glatt Quick sieve or the like is used, the particle size becomes fixed. The objects, features and advantages of the present invention are given by way of example, without any limitation of the invention, although there may be some examples. The tablet hardness is an average value of 10 tablet hardness, and the tablet weight is an average value of 20 tablet weight. Examples 1-3 Acetaminophen composition granule fluidized bed granulation dryer (Gl
att Air Technologies, Inc. GP
CG-1). The number of machines and prescriptions are shown in Table 3,
Particle size distribution (particle size) and cumulative ratio (c
umulative permanent retaine
d) was tested under the conditions shown in Table 4. As a result, the concentration of the polyvinylpyrrolidone (PVP) aqueous solution is 5% and the flowability of 7.5% w / v can be directly tableted. [Table 3] [Table 4] Examples 4-6 Direct compression drug compositions were prepared using the samples shown in Table 5 below, the properties of which are shown in Table 6: [Table 6]

Claims (1)

【特許請求の範囲】 (1)(A)ジアセチル−P−アミノフェノール(ac
etyl−P−aminophenol)流動床に置
く,(B)ポリビニルピロリドン(polyvinyl
pyrolidone,PVP)を水で溶け,5〜10
w/v%溶液になる,この溶液は流量20〜35%の流
動床にあるジアセチル−P−アミノフェノール粉末に噴
霧する,(C)噴霧させたジアセチル−P−アミノフェ
ノール粉末は流動床の氛囲気の湿度0.5〜2重量百分
率まで乾燥させる,(D)流動化を止めるともに1〜5
%崩壊剤を加えて,(E)湿度は0.5〜2重量百分率
まで上記の各成分は流動床で充分に混合させ,(F)直
接打錠する。上記(A)から(F)の手順までを含有す
ることを特徴とするジアセチル−P−アミノフェノール
錠剤の製造法。 (2)前記錠剤の製造法において崩壊剤はポリビニルピ
ロリドン(PVP)crospovidoneを含
む特許請求の範囲第1項記載の組成物。 (3)前記錠剤の製造法において崩壊剤はデンプンエチ
レンオキシドナトリウム(Soldiumstarch
glycolate)を含む特許請求の範囲第1項記
載の組成物。 (4)錠剤は前記特許請求範囲第1項記載の方法である
錠剤製造法から製造した組成物。
Claims (1) (A) Diacetyl-P-aminophenol (ac
etyl-P-aminophenol) placed in a fluidized bed, (B) polyvinylpyrrolidone (polyvinyl)
Pyrolidone (PVP) is dissolved in water, 5-10
It becomes a w / v% solution, which is sprayed on diacetyl-P-aminophenol powder in a fluidized bed with a flow rate of 20-35%, (C) The sprayed diacetyl-P-aminophenol powder is a fluidized bed drip. Humidity of the atmosphere is dried to 0.5 to 2% by weight, (D) Fluidization is stopped and both are 1 to 5
% Disintegrant is added, and (E) the humidity is adjusted to 0.5 to 2 weight percent, the above components are sufficiently mixed in a fluidized bed, and (F) direct compression is performed. A method for producing a diacetyl-P-aminophenol tablet, which comprises the steps (A) to (F) above. (2) The composition according to claim 1, wherein the disintegrant in the tablet manufacturing method contains polyvinylpyrrolidone (PVP) crospovidone. (3) In the above tablet manufacturing method, the disintegrant is sodium starch ethylene oxide (Soldiumstarch).
A composition according to claim 1, which comprises a glycolate. (4) The tablet is a composition produced by the tablet production method, which is the method described in claim 1.
JP19261592A 1992-06-10 1992-06-10 Pharmaceutical composition which can be directly made into tablet and preparation of said tablet Pending JPH0656659A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP19261592A JPH0656659A (en) 1992-06-10 1992-06-10 Pharmaceutical composition which can be directly made into tablet and preparation of said tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19261592A JPH0656659A (en) 1992-06-10 1992-06-10 Pharmaceutical composition which can be directly made into tablet and preparation of said tablet

Publications (1)

Publication Number Publication Date
JPH0656659A true JPH0656659A (en) 1994-03-01

Family

ID=16294211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP19261592A Pending JPH0656659A (en) 1992-06-10 1992-06-10 Pharmaceutical composition which can be directly made into tablet and preparation of said tablet

Country Status (1)

Country Link
JP (1) JPH0656659A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693281A3 (en) * 1994-07-20 1996-10-30 Lilly Sa Fluoxetine Pharmaceutical formulations
JP2002540153A (en) * 1999-03-26 2002-11-26 ビオシント・ソシエタ・ペル・アチオニ Granules high in L-carnitine or alkanoyl L-carnitine
JP2003509368A (en) * 1999-09-16 2003-03-11 ローディア・インコーポレイテッド Directly compressible ultrafine acetaminophen composition and method for producing the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57130913A (en) * 1980-12-22 1982-08-13 Monsanto Co Direct compress analgesic drug granulating composition, tablets thereof and manufacture
JPS601141A (en) * 1983-06-17 1985-01-07 Idemitsu Kosan Co Ltd Production of xylene
JPH01305955A (en) * 1988-04-15 1989-12-11 Basf Ag Production of mixture for preparation
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57130913A (en) * 1980-12-22 1982-08-13 Monsanto Co Direct compress analgesic drug granulating composition, tablets thereof and manufacture
JPS601141A (en) * 1983-06-17 1985-01-07 Idemitsu Kosan Co Ltd Production of xylene
JPH01305955A (en) * 1988-04-15 1989-12-11 Basf Ag Production of mixture for preparation
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693281A3 (en) * 1994-07-20 1996-10-30 Lilly Sa Fluoxetine Pharmaceutical formulations
EP1070501A1 (en) * 1994-07-20 2001-01-24 Lilly S.A. Method of preparing a dispersible fluoxetine tablet
EP1072262A1 (en) * 1994-07-20 2001-01-31 Lilly S.A. Dispersible fluoxetine tablet
JP2002540153A (en) * 1999-03-26 2002-11-26 ビオシント・ソシエタ・ペル・アチオニ Granules high in L-carnitine or alkanoyl L-carnitine
JP4637367B2 (en) * 1999-03-26 2011-02-23 ビオシント・ソシエタ・ペル・アチオニ L-carnitine or alkanoyl L-carnitine high content granule
JP2003509368A (en) * 1999-09-16 2003-03-11 ローディア・インコーポレイテッド Directly compressible ultrafine acetaminophen composition and method for producing the same

Similar Documents

Publication Publication Date Title
JPS62174013A (en) Vitamin granule for direct tableting, production thereof and tablet prepared therefrom
JPS62120323A (en) Long life release type composition containing hydroxypropylcellulose ether
JPS62149632A (en) Solid medicine
JPH1067651A (en) Auxiliary agent for direct tableting, tablet comprising the same auxiliary agent and production of tablet
EP0456720B1 (en) High ibuprofen content granulations
JP2009524658A (en) Levetiracetam preparation and method for producing the same
CA2737380C (en) Tabletting excipient based on lactose and cellulose
JPS6191118A (en) Granule of thiamine salt, its production, and tablet
US3836618A (en) Process for the uniform distribution of a drug on a granulated base
KR20070113297A (en) Agglomerated starch compositions
TWI468178B (en) Solid preparation of solid dispersion and method for producing the same
JP4070402B2 (en) Low substituted hydroxypropylcellulose and process for producing the same
JP3850189B2 (en) Solid preparation and production method thereof
JP6453740B2 (en) Alkylcellulose for tableting and solid preparation containing the same
JPH05320045A (en) Spray drying method for manufacturing medicine powder composition being compressable directly to tablet
EP2603288A1 (en) Pharmaceutical granulate comprising imatinib mesylate
JP2002104956A (en) Base for dry direct compressing hydroxypropylcellulose having low substitution degree
JP4822096B2 (en) Herbal powder-containing tablets
JPH0656659A (en) Pharmaceutical composition which can be directly made into tablet and preparation of said tablet
KR20180019486A (en) Low-substituted hydroxypropyl cellulose and solid preparation
JP4379853B2 (en) Direct tableting formulations and methods of formulating adjuvants
JP4774739B2 (en) Kampo extract-containing tablet composition and method for producing the same
CN106176655B (en) Penicillin V potassium tablet and preparation process thereof
KR20180052127A (en) Tablets with medium independent active material transfer
CN104306376A (en) Paracetamol, aminophenazone, caffeine and chlorphenamine maleate tablet and preparation method thereof